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Abstract: A new class of compounds that incorporated the structural motif of the 1-(γ’,4’,5’-
trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton was synthesized and 
evaluated for their antiproliferative activity in vitro, interactions with tubulin and cell cycle effects. 
The most active agent, 3c, was evaluated for antitumor activity in vivo. Structure-activity 
relationships were elucidated with various substituents on the phenyl ring of the anilino moiety at 
the C-3 position of the 1,2,4-triazole ring. The best results for inhibition of cancer cell growth were 
obtained with the p-Me, m,p-diMe and p-Et phenyl derivatives 3c, 3e and 3f, respectively, and, 
overall, these compounds were more or less as active as CA-4. Their vascular disrupting activity 
was evaluated in HUVEC cells, with compound 3c showing activity comparable with that of CA-4. 
Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/c mice, 
suggesting that 3c could be a new antimitotic agent with clinical potential.  
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Introduction 
The cellular microtubule system, established by an equilibrium between the polymerization and 
depolymerization of α-tubulin heterodimers, is essential in a variety of cellular processes, 
including maintenance of cell shape, regulation of motility, intracellular transport of vesicles and 
organelles and cell division.1 Due to the latter function in eukaryotic cells, microtubules are a 
successful target for the development of numerous small natural and synthetic molecules that inhibit 
the formation of the mitotic spindle.2-4 Among the naturally occurring antimicrotubule agents, one 
of the most active is the cis-stilbene combretastatin A-4 (CA-4, 1a, Chart 1), isolated from the 
African cape bushwillow Combretum caffrum.5 CA-4 inhibits tubulin assembly by strongly binding 
to the colchicine site on -tubulin.6 Its water soluble prodrug, CA-4 disodium phosphate (CA-4P, 
1b),7 is in advanced clinical trials,8 and it was found to have potent activity in reducing tumor blood 
flow, thus acting as a vascular disrupting agent (VDA).9  
Among the synthetic inhibitors of tubulin polymerization, we previously described a series of 2-
arylamino-4-amino-5-(γ’,4’,5’-trimethoxybenzoyl)thiazoles with general structure 2 that showed 
strong antiproliferative activity against a panel of five cancer cell lines.10 These compounds also 
caused accumulation of HeLa cells in the G2/M phase of the cell cycle, as is typical for 
antimicrotubule agents. Derivatives 2a (R1=H) and 2b (R1=4’-Me) were the most active as 
inhibitors of tumor cell growth, with IC50 values of 6-23 and 15-86 nM, respectively, in the five cell 
lines.  
Ring bioisosterism is widely used as a rational approach for the discovery of new anticancer agents, 
especially for finding agents with optimal pharmacological properties.11 Continuing our search 
strategy for novel and potent antimicrotubule agents, we have underway a pharmacophore 
exploration and optimization effort based on compounds with general formula 2. Here we describe 
replacing the thiazole nucleus with the more electron-rich 1,2,4-triazole bioisosteric ring,12,13 to 
afford a new series of 1-(γ’,4’,5’-trimethoxybenzoyl)-3-arylamino-5-amino 1,2,4-triazole analogues 
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with general structure 3. Our goal was to evaluate the steric and electronic effects of different 
substituents on the benzene portion of the arylamino moiety. Besides hydrogen (compound 3a), the 
examined substituents included fluorine (3b) and electron donating alkyl and alkoxy groups 
(compounds 3c-h and 3i-n, respectively). Since it is well known that the trimethoxyphenyl skeleton 
is the characteristic structural requirement to maximize activity in a large series of inhibitors of 
tubulin polymerization, such as colchicine, CA-4 and podophyllotoxin,14 all newly prepared 
compounds 3a-n, retain the γ’,4’,5’-trimethoxybenzoyl group at the C-1 position of the 1,2,4-
triazole ring. The newly synthesized derivatives were evaluated for their antiproliferative activity in 
a panel of human cancer cell lines, for their antitubulin activity (including cell cycle and apoptotic 
effects) and their antivascular activity in HUVEC cells. Finally, the antitumor activity of 3c, the 
most potent member of the group in the in vitro studies, was evaluated in vivo in a syngeneic 
hepatocellular carcinoma in Balb/c mice in comparison with CA-4P.  
Chemistry 
Synthesis of compounds 3a-n was accomplished using a three-step procedure described in Scheme 
1. The condensation of dimethyl cyanodithioimidocarbonate 415 with the appropriate substituted 
aniline resulted in the formation of imidates 5a-n, which were cyclized into the corresponding 5-
amino-1H-[1,2,4]-triazole derivatives 6a-n in the presence of hydrazine hydrate in refluxing THF.16 
Treatment of 6a-n with an equimolar quantity of γ’,4’,5’-trimethoxybenzoyl chloride resulted in the 
formation of compounds 3a-n as the major regioisomers. In the synthesis of compounds 3a-c, 3g-h 
and 3k-l, the corresponding minor regioisomers 7a-c, 7g-h and 7k-l, respectively, were also isolated 
in pure form and low yields (5-12%).  
X-ray crystallographic analysis of a representative compound (3c) was determined to confirm the 
regioselective aroylation at the less sterically hindered N-1 nitrogen of the 1,2,4-triazole ring. Single 
crystals of 3c were grown by slow evaporation from i-PrOH-MeOH solution, and the ORTEP view 
of compound 3c is shown in Figure 1. The molecule displays an intramolecular N4-H…O1 
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hydrogen bond having N4…O1 and H…O1 distances of β.77γ(γ) and β.1β(γ) Å, respectively, and 
an N4-H…O1 angle of 1β8(β)°. 
Biological Results and Discussion 
In vitro antiproliferative activities. Table 1 summarizes the antiproliferative effects of 1-(γ’,4’,5’-
trimethoxybenzoyl)-3-anilino-5-amino 1,2,4-triazoles 3a-n against a panel of seven human cancer 
cell line, using CA-4 (1) as the reference compound. The 1-(γ’,4’,5’-trimethoxybenzoyl)-3-amino-5-
anilino 1,2,4-triazole isomers 7a-c, 7g-h and 7k-l were also evaluated for their activities, but, since 
they were all inactive (IC50>10 M), the data are not shown in Table 1. Three of the synthesized 
compounds, corresponding to the p-Me, m,p-di-Me and p-Et phenyl analogues 3c, 3e and 3f, 
respectively, were significantly more active than the rest of derivatives, with IC50 values of 0.21-3.2, 
0.4-4.0, and 0.21-6.0 nM, respectively, in the seven cell lines, as compared with 4-3100 nM for CA-
4. With average IC50 values of 1.0, 1.9 and 2.4 nM for 3c, 3e and 3f, respectively, 3c appears to be 
the most active compound in the series (for CA-4, the average value was 525 nM or, excluding the 
HT-29 cell line from the average, 96 nM). Thus, these three compounds are substantially more 
active than CA-4, and they are also more potent than their previously described isosteres 2a and 
2b.11 In addition to these highly potent three derivatives, the m-OMe and m,p-methylenedioxy 
phenyl derivatives 3j and 3n, respectively, were more active than CA-4 against HT-29, A549 and 
MCF-7 cells. In short, the data shown in Table 1 indicate the importance of substituents and their 
relative position on the phenyl ring of the arylamino moiety at the C-3 position of the 1,2,4-triazole 
skeleton for activity and selectivity against different cancer cell lines. 
The unsubstituted anilino derivative 3a was weakly active (IC50>0.5 M), and the introduction of a 
weak electron-releasing fluorine atom at the para-position of the phenyl (compound 3b) had the 
opposite effect, with slightly improved antiproliferative activity with respect to 3a against HeLa, 
HT-29, A549 and MCF-7 cells, while the activity was reduced against Jurkat, CCRF-CEM and 
SEM cells.  
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We found that the small methyl group at the para-position of the phenyl ring, to furnish derivative 
3c, improved significantly antiproliferative activity relative to 3a. Moving the methyl group from 
the para- to the meta-position, to furnish isomer derivative 3d, reduced antiproliferative activity 
from one to three orders of magnitude, with double digit nanomolar activity against Jurkat, SEM 
and MCF-7 cells. Since the para-toluidino moiety of 3c was favorable for potency, it is important to 
point out that the introduction of an additional methyl group at the meta-position, resulting in the 
meta, para-dimethyl derivative 3e, produced a 2- to 4-fold reduction in antiproliferative activity 
against five of the six cancer cell lines, while 3c and 3e were equipotent against SEM and HeLa 
cells.  
The para-ethyl homologue 3f was 2-15-fold less active than methyl counterpart 3c against four of 
the seven cancer cell lines, with a minimal difference between the two compounds in the Jurkat and 
SEM cells, while 3f was 4-fold more potent than 3c against HT-29 cells. Replacing the para-ethyl 
group with branched (i-Pr) or larger (n-butyl) moieties (compounds 3g and 3h, respectively) was 
detrimental for activity in all cell lines, suggesting that an increase in steric bulk at this position 
caused a decrease in potency.  
The number and position of methoxy substituents on the phenyl ring (compounds 3i-l) had a major 
influence on antiproliferative activity. Replacement of the methyl moiety with a more electron-
releasing methoxy group at the para-position of the phenyl ring (compound 3i) decreased 
antiproliferative activity by 100-fold compared with 3c, indicating that the methyl and methoxy 
groups are not bioequivalent at the para-position of the phenyl ring. The contribution of methyl or 
methoxy groups on the phenyl ring to activity (3c vs. 3d and 3i vs. 3j, respectively) was position 
dependent, with opposite effects. While for the methyl group, as previously observed, the para-
derivative 3c was considerably more potent than meta-isomer 3d, an opposite effect was observed 
for the two methoxy isomers 3i and 3j, with the meta-isomer 3j from 4- to 44-fold more potent than 
the para-isomer 3i in six of the seven cancer cell lines, the exception being the HT-29 cells. Either 
two or three methoxy substituents (derivatives 3k and 3l, respectively) caused substantial loss in 
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antiproliferative activity relative to 3i and 3j, suggesting that steric factors account for the loss of 
activity observed with these two compounds. With the exception of the MCF-7 cells, the para-
ethoxy derivative 3m was 2- to 50-fold less potent than its methoxy counterpart 3m. The γ’,4’-
methylenedioxy derivative 3n, with IC50 values in the double-digit nanomolar range in five of the 
seven cancer cell lines, showed an antiproliferative activity intermediate between those of para- and 
meta-methoxy analogues 3i and 3j, respectively. 
Evaluation of cytotoxicity in human non-cancer cells. To obtain a preliminary indication of the 
cytotoxic potential of these derivatives for normal human cells, two of the most active compounds 
(3c and 3f) were assayed in vitro against peripheral blood lymphocytes (PBL) from healthy donors 
(Table 2). Both compounds were practically ineffective in quiescent lymphocytes, with an IC50 of 
about 30 µM. In the presence of  the mitogenic stimulus phytohematoagglutinin (PHA), the IC50 
decreased to about 8 µM for both compounds, a value that is thousands of times higher than those 
observed against the lymphoblastic cell lines Jurkat and CCRF-CEM. Furthermore, compound 3c 
was also evaluated in human umbilical vein endothelial cells (HUVECs), and again the IC50 value 
was negligible compared with those found in the panel of cancer cell lines. Altogether these data 
suggest that these compounds may have cancer cell selective antiproliferative properties. 
Effect of compound 3c on drug-resistant cell lines 
Drug resistance has become a serious problem in cancer chemotherapy.17,18 One of the common 
mechanisms of resistance so far identified  both in preclinical and clinical studies involves the 
overexpression of a cellular membrane protein called P-glycoprotein (P-gp) that mediates the efflux 
of various structurally unrelated drugs.17,18 We evaluated sensitivity of compound 3c in two 
multidrug-resistant cell lines, one derived from a colon carcinoma (LovoDoxo),19 the other derived 
from a lymphoblastic leukemia (CEMVbl-100).20 Both these lines express high levels of the P-gp.19,20 
As shown in Table 3, compound 3c was almost equally potent toward cells resistant to doxorubicin 
or vinblastine showing a resistance index (RI), which is the ratio between GI50 values of resistant 
 8 
cells and sensitive cells, of 1.2 and 5.7 respectively, while doxorubicin in LoVoDoxo and vinblastine 
in CEMVbl100 showed a high RI of 118 and 193, respectively. Altogether these results suggest that 
this compound might be useful in the treatment of drug refractory tumors. 
Inhibition of tubulin polymerization and colchicine binding. A subset of the compounds (3c-g, 
3i-j and 3n) were evaluated for their in vitro inhibition of tubulin polymerization in comparison 
with CA-4. The same compounds were also examined for inhibitory effects on the binding of 
[3H]colchicine to tubulin (Table 4). In the assembly assay, with 10 µM tubulin, compound 3c was 
highly potent, yielding an IC50 of 0.75 M, almost twice as active as CA-4. Derivatives 3e and 3f 
had IC50 values of 1.2 and 1.4 M, comparable to the value obtained with CA-4. Compounds 3d, 3i-
j and 3n were less active as inhibitors of tubulin polymerization, with IC50 values of 1.8, 3.7, 2.5 
and 2.0 M, respectively, while 3g was, relatively speaking, almost inactive. The order of inhibitory 
effects on tubulin assembly was 3c>3e=CA-4>3f>3d>3n>3j>3i>>3g. This order of activity as 
inhibitors of tubulin assembly correlates well with their order of activity as antiproliferative agents 
against Jurkat, CCRF-CEM, SEM and HeLa cells. 
In the competition assay, compound 3c was again the most active derivative, inhibiting colchicine 
binding by 92%, versus 98% for CA-4. In the experiments summarized in Table 4, the concentration 
of tubulin was 1.0 µM, while that of both the inhibitors and [3H]colchicine was 5.0 µM. Inhibition 
of colchicine binding by compounds 3e and 3f was lower, with 83% and 80% inhibition occurring 
with these agents. With the exception of compounds 3j and 3n, a good correlation was observed 
between antiproliferative activities, inhibition tubulin polymerization and inhibition of colchicine 
binding. 
To further investigate if the new derivatives interfered with the microtubule network, we examined 
the effects of 3c on HeLa cells by immunofluorescence microscopy. Following a 24 h treatment 
with 3c at 50, 100 and 250 nM, the microtubule network was substantially modified in comparison 
with the untreated cells (Figure S1, Supporting Information). Altogether these results are consistent 
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with the conclusion that the antiproliferative activity of these compounds derived from an 
interaction with the colchicine site of tubulin, and this ultimately results in interference with 
microtubule assembly.  
Molecular Modeling. To rationalize the experimental data observed for 3a-n, we performed a 
series of molecular docking simulations of these compounds in the colchicine site of tubulin. The 
proposed binding mode for 3c is very similar to the one presented by the co-crystallized DAMA-
colchicine (Figure 2, panel A). In particular, it is possible to observe how the trimethoxyphenyl ring 
is in proximity of Cys241, while the phenyl ring occupies a hydrophobic region deep in the binding 
site, establishing a series of interactions with Met259, Thr314 and Lys352. Indeed, this sub-pocket 
is relatively small and, while the methyl substituent on the phenyl ring of 3c is able to fit in 
properly, larger groups, such as the isopropyl (3g) or the n-butyl (3h), cannot be accommodated into 
it. In these cases, the docking simulations are not able to generate a reasonable binding pose. The 
docking results are in accordance with the experimental data, and they provide a possible structural 
justification of the SARs observed (Figure 2, panel B). Finally, it is interesting to note that the 3c 
binding conformation generated in the docking simulation is very similar to the conformation of the 
structure obtained experimentally by X-ray crystallography (Figure 2, panel C).  
Analysis of 3-arylamino 1,2,4-triazole derivatives for effects on the cell cycle. The effects of a 
24 h treatment with different concentrations of 3c on cell cycle progression in HeLa and Jurkat cells 
were determined by flow cytometry (Figure 3, panels A, B). The compound caused a significant 
G2/M arrest in a concentration-dependent manner in the cell lines tested, with a rise in G2/M cells 
occurring at a concentration as low as 60 nM, while, at higher concentrations, more than 70% of the 
cells were arrested in G2/M. The cell cycle arrest in the G2/M phase was accompanied by a 
corresponding reduction in cells in the other phases of the cell cycle. In particular, the G1 phase 
decreased in both cell lines whereas S phase reduction was mainly evident in Jurkat cells. 
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We next studied the association between 3c-induced G2/M arrest and alterations in expression of 
proteins that regulate cell division. As shown in Figure 4 in HeLa cells, a 24 h treatment with 3c at 
concentrations lower than 100 nM caused no significant variation in cyclin B expression, which, in 
association with cdc2 controls both entry into and exit from mitosis,21,22 while at 100 and 250 nM 
we observed a clear increase in the cyclin B1 band. After a 48 h treatment, cyclin B1 expression 
decreased. More importantly, p-cdc2Tyr15 expression decreased after either 24 or 48 h of treatment. 
However, no major changes in the expression of phosphatase cdc25c were observed. These results 
indicate that arrest at G2/M induced by 3c is caused by an immediate block of cyclin B1 activity, 
followed by its accumulation, leading to a persistent and marked decrease of p-cdc2 Tyr15 more 
detectable at the highest concentrations (100-250 nM) examined. 
In addition to the analysis of proteins that control cell cycle checkpoints, we also examined the 
expression of the tumor suppressor p53 after treatment of Hela cells with 3c. It is well known that 
prolonged mitotic arrest induces DNA damage and, consequently, p53 up-regulation.23,24 As shown 
in Figure 4 (panel B), we detected in a concentration-dependent manner an increase in p53 
expression that is particularly evident after 48 h of treatment. At the same time, we also observed a 
marked increase in the expression of phosphorylated histone ȖHβA.X, which is an early sensitive 
indicator of DNA damage.25 Interestingly, the expression of the cyclin-dependent kinase inhibitor 
p21, which was previously demonstrated to have an anti-apoptotic role,26 decreased both after 24 
and 48 h of treatment. 
Compound 3c induces apoptosis. To characterize the mode of cell death induced by 3c, a 
biparametric cytofluorimetric analysis was performed using propidium iodide (PI), which stains 
DNA and enters only dead cells, and fluorescent immunolabeling of the protein annexin-V, which 
binds to phosphatidylserine (PS) in a highly selective manner.27  Dual staining for annexin-V and 
with PI permits discrimination between live cells (annexin-V-/PI-), early apoptotic cells (annexin-
V+/PI-), late apoptotic cells (annexin-V+/PI+) and necrotic cells (annexin-V-/PI+). As shown in 
Figure 5, both HeLa (panel A) and Jurkat cells (panel B) treated with the two compounds for 24 h 
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showed an accumulation of annexin-V positive cells that further increased after 48 h in comparison 
with the untreated cells. Analogous results were also obtained for compound 3e (see Figure S2, 
Supporting Information). 
Compound 3c induces caspase-dependent apoptosis. We then analyzed by western blot which 
proteins are involved on the triggered apoptotic pathway upon treatment with 3c. HeLa cells were 
treated with different concentrations of 3c for 24 or 48 h (Figure 6). Interestingly, 3c induced 
activation of the initiator caspase-9 in a time and concentration-dependent manner. We observed 
also an activation of the effector caspase-3 and cleavage of its substrate PARP (Figure 6, panel A). 
Furthermore, the anti-apoptotic protein Bcl-2 was decreased by treatment with 3c in a time 
dependent manner, while the expression of a pro-apoptotic protein, Bax was slightly increased only 
at 250 nM and at 48 h. 
Derivative 3c has antivascular effects in vitro. Tumor growth requires an oxygen supply, so the 
tumor microenvironment stimulates the development of additional blood vessels.28 Recent 
antitumor strategies are based on the use of chemotherapeutics with anti-angiogenic or anti-vascular 
drugs, in order to increase the efficacy of the treatment.29 Many tubulin binding agents show 
antivascular effects against tumor endothelium,30 including CA-4, and for that reason we evaluated 
3c for effects on endothelial cells in vitro. We used human umbilical vein endothelial cells 
(HUVECs) as a model for angiogenesis/vasculogenesis processes in vitro. Endothelial cell 
migration to the tumor site is one of the described mechanisms of angiogenesis.31 Inhibiting this 
mechanism could be a strategy to arrest the development of tumor vasculature. We evaluated cell 
motility by scratching a HUVEC monolayer and monitoring the ability of cells to reclose the 
wound. As shown in Figure 7, (panel A), 3c is very efficient in arresting cell motility. The effect is 
statistically significant after a 24 h incubation, at all the tested concentrations (5, 10, 25 nM), while, 
after 6 h, 3c significantly inhibited cell motility at 10 and 25 nM, with a dose-response relationship 
observed (Figure 7, panel B). 
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To support the antivascular activity of 3c we evaluated the ability of the compound to disrupt the 
“tubule-like” structures, formed by HUVECs seeded on Matrigel. Matrigel is an extracellular 
matrix, rich in pro-angiogenic factors that stimulate single endothelial cells to assume an extended 
shape. The overall effect results in a reticulum similar to a capillary network. 
As shown in Figure 7, panel C, after a 1 h incubation, 25 nM 3c visibly disrupted the network of 
HUVECs, as compared with the control. After 3 h, all the tested concentrations were effective in 
altering the tubule-like structures. An image analysis32 was performed to obtain a quantitative 
measurement of the total length of the tubules, the area and the number of meshes, the percent of 
area covered by HUVECs, and the number of branching points (Figure 7, panel D) after a 3 h 
treatment. 
The results indicate that the effects on endothelial cells induced by 3c are similar to those observed 
after CA-4 treatment, in the same experimental conditions, carried out by our group.33 
Evaluation of antitumor activity of compound 3c in vivo. To evaluate the in vivo antitumor 
activity of 3c, a syngeneic hepatocellular carcinoma model in mice was used.34 Tumors were 
established by subcutaneous injection of BNL 1ME A.7R.1 cells into the backs of Balb/c mice. In 
preliminary experiments in vitro, we determined that both compound 3c and CA-4, used as a 
reference compound, showed similar, potent cytotoxic activity (3c IC50=3.4±1.1 nM; CA-4 
IC50=1.1±0.5 nM) against BNL 1ME A.7R.1 cells. Once the allografts reached a measurable size 
(about 100 mm3), twenty mice were randomly assigned to one of four groups. In two of the groups, 
compound 3c was injected intraperitoneally at doses of 5 and 10 mg/kg, respectively. In a third 
group, CA-4P was injected at 5 mg/kg, while the fourth group was used as a control. As depicted in 
Figure 8 (panel A), compound 3c caused a significant reduction in tumor growth, as compared with 
administration of vehicle, at 10 but not 5 mg/kg. The effect of 5 mg/kg of CA-4P was not as great as 
that of 10 mg/kg of 3c, but the CA-4P effect was still significant relative to the control. During the 
treatment period, only a small decrease in body weight occurred in the 3c-treated animals (Figure 8, 
Panel B). 
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Conclusions 
The bioisosteric equivalence between thiazole and 1,2,4-triazole prompted us to synthesize a series 
of 1-(3’,4’,5’-trimethoxybenzoyl)-3-arylamino-5-amino 1,2,4-triazole derivatives with general 
formula 3, in which the 1,2,4-triazole ring replaced the thiazole system of previously published 
analogues with general structure 2. The substitution pattern on the phenyl of the arylamino moiety 
had variable effects.  
Compound 3c, bearing a p-toluidino moiety at the C-3 position of 1,2,4-triazole ring, its p-ethyl 
homologue 3f and the m,p-dimethyl analogue 3e exhibited the greatest antiproliferative activity 
among the tested compounds, with IC50 values of 0.21-3.2, 0.21-6.0 and 0.4-4.0 nM, respectively. 
These results were superior or comparable with those of the reference compound CA-4 against all 
cancer cell lines. The para-position tolerates small substituents, such as methyl (3c) or ethyl (3f) 
groups, while the inactivity of i-Pr or n-Bu derivatives 3g and 3h, respectively, indicates that bulky 
substituents were detrimental for activity. Placing the methyl group in the meta-position (3d) led to 
a dramatic drop in potency as compared with the para-isomer 3c, even though we observed 
excellent activity with the meta, para-dimethyl derivative 3e. Compound 3c was the most potent 
inhibitor of tubulin polymerization and of colchicine binding (IC50=0.75 M for assembly, 92% 
inhibition of the binding of 5 M colchicine), and the antiproliferative activity of 3c, in terms of 
IC50’s, ranged from 0.21 to 3.2 nM in the seven cell tumor lines examined, values lower than that of 
previously published isosteric analogues.11 In addition, in preliminary experiment 3c had low 
toxicity in non tumoral cells and is active also in drug-resistant cell lines. Although 3c was almost 
twice as active as CA-4 as an inhibitor of tubulin polymerization, these two compounds showed 
similar activity as inhibitors of colchicine binding. Moreover, in a detailed series of biological 
assays, we clearly demonstrated that 3c induced caspase-dependent apoptosis and late DNA damage 
and p53 induction. Compound 3c, in addition to its ability to inhibit tubulin polymerization, 
efficiently targeted endothelial cells, acting as a VDA. More importantly, in vivo experiments 
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showed that this compound was able to significantly reduce the growth of a syngeneic tumor model 
in mice, indicating that it is a very promising anticancer compound that warrants further evaluation 
for its potential clinical use. 
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Experimental Section 
Chemistry. Materials and Methods. 
1H and 13C NMR data were obtained with a Varian VXR 200 
spectrometer and a Varian Mercury Plus 400 spectrometer, respectively. Peak positions are given in 
parts per million () downfield, and J values are given in hertz. Positive-ion electrospray ionization 
(ESI) mass spectra were recorded on a double-focusing Finnigan MAT 95 instrument with BE 
geometry. Melting points (mp) were determined on a Buchi-Tottoli apparatus and are uncorrected. 
The purity of tested compounds was determined by combustion elemental analyses conducted by the 
Microanalytical Laboratory of the Chemistry Department of the University of Ferrara with a 
Yanagimoto MT-5 CHN recorder elemental analyzer. All tested compounds yielded data consistent 
with a purity of at least 95% as compared with the theoretical values. All reactions were carried out 
under an inert atmosphere of dry nitrogen, unless otherwise indicated. TLC was carried out using 
glass plates coated with silica gel 60 F254 by Merck, and compounds were visualized by UV 
detection or with aqueous KMnO4. Flash column chromatography was performed using 230-400 
mesh silica gel and the indicated solvent system. Organic solutions were dried over anhydrous 
Na2SO4. Solvents and reagents that are commercially available were purchased from Aldrich 
(Sigma-Aldrich) or Alfa Aesar (Johnson Matthey Company) and were used without further 
purification unless otherwise noted. 
General procedure A for the synthesis of compounds 5a-n. To a solution of the appropriate 
aniline derivative (3 mmol, 1 equiv.) in isopropanol (10 mL) was added dimethyl 
cyanodithioimidocarbonate 4 (439 mg, 3 mmol), and the mixture was refluxed for 16 h. After this 
time, the solvent was removed under reduced pressure, the resulting residue was suspended in ethyl 
ether (10 mL) and filtered to furnish the final compound 5a-n used for the next reaction without any 
purification. 
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(Z)-Methyl N'-cyano-N-phenylcarbamimidothioate (5a). Synthesized according to method A, 
derivative 5a was obtained as a white solid (yield 71%); mp 192-193 °C. 1H-NMR (CDCl3) : 2.46 
(s, 3H), 7.38 (m, 5H), 7.92 (bs, 1H). MS (ESI): [M+1]+=192.3. 
(Z)-Methyl N'-cyano-N-(4-fluorophenyl)carbamimidothioate (5b). Synthesized according to 
method A, compound 5b was obtained as a grey solid (yield 78%); mp 216-218 °C. 1H-NMR 
(CDCl3) : 2.45 (s, 3H), 7.12 (t, J=8.0 Hz, 2H), 7.29 (m, 2H), 7.94 (bs, 1H). MS (ESI): 
[M+1]+=210.3. 
(Z)-Methyl N'-cyano-N-(p-tolyl)carbamimidothioate (5c). Synthesized according to method A, 
derivative 5c was isolated as a white solid (yield 67%); mp 152-154 °C. 1H-NMR (CDCl3) : 2.38 
(s, 3H), 2.43 (s, 3H), 7.14 (dd, J=9.0 and 2.6 Hz, 2H), 7.19 (dd, J=9.0 and 2.6 Hz, 2H), 7.97 (bs, 
1H). MS (ESI): [M+1]+=206.1. 
(Z)-Methyl N'-cyano-N-(3-methylphenyl)carbamimidothioate (5d). Synthesized according to 
method A, derivative 5d was obtained as a white solid (yield 52%); mp 148-150 °C. 1H-NMR 
(CDCl3) : 2.39 (s, 3H), 2.44 (s, 3H), 6.81 (m, 1H), 6.93 (s, 1H), 7.03 (m, 2H), 7.82 (bs, 1H). MS 
(ESI): [M+1]+=206.2. 
(Z)-Methyl N'-cyano-N-(3,4-dimethylphenyl)carbamimidothioate (5e). Synthesized according to 
method A, derivative 5e was obtained as a white solid (yield 87%); mp 138-140 °C. 1H-NMR 
(CDCl3) : 2.27 (s, 6H), 2.43 (s, 3H), 7.05 (m, 2H), 7.14 (d, J=7.8 Hz, 1H), 7.84 (bs, 1H). MS 
(ESI): [M+1]+=220.2. 
(Z)-Methyl N'-cyano-N-(4-ethylphenyl)carbamimidothioate (5f). Synthesized according to 
method A, compound 5f was obtained as a white solid (yield 68%); mp 159-161 °C. 1H-NMR 
(CDCl3) : 1.25 (t, J=7.6 Hz, 3H), 2.43 (s, 3H), 2.62 (q, J=7.6 Hz, 2H), 7.17 (dd, J=9.0 and 2.8 Hz, 
2H), 7.24 (dd, J=9.0 and 2.8 Hz, 2H), 7.90 (bs, 1H). MS (ESI): [M+1]+=220.4. 
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(Z)-Methyl N'-cyano-N-(4-isopropylphenyl)carbamimidothioate (5g). Synthesized according to 
method A, derivative 5g was obtained as a white solid (yield 64%); mp 129-131 °C. 1H-NMR 
(CDCl3) : 1.26 (d, J=7.0 Hz, 6H), 2.44 (s, 3H), 2.93 (m, 1H), 6.89 (dd, J=8.4 and 2.4 Hz, 2H), 7.22 
(dd, J=8.4 and 2.4 Hz, 2H), 7.93 (bs, 1H). MS (ESI): [M+1]+=234.4. 
(Z)-Methyl N-(4-n-butylphenyl)-N'-cyanocarbamimidothioate (5h). Synthesized according to 
method A, derivative 5h was obtained as a white solid (yield 63%); mp 149-151 °C. 1H-NMR 
(CDCl3) : 0.93 (t, J=7.4 Hz, 3H), 1.33 (m, 2H), 1.59 (m, 2H), 2.43 (s, 3H), 2.63 (t, J=7.8 Hz, 2H), 
7.17 (dd, J=8.8 and 2.4 Hz, 2H), 7.24 (dd, J=8.8 and 2.4 Hz, 2H), 7.93 (bs, 1H). MS (ESI): 
[M+1]+=248.4. 
(Z)-Methyl N'-cyano-N-(4-methoxyphenyl)carbamimidothioate (5i). Synthesized according to 
method A, compound 5i was obtained as a purple solid (yield 91%); mp 193-195 °C. 1H-NMR 
(CDCl3) : 2.41 (s, 3H), 3.83 (s, 3H), 6.89 (d, J=8.8 Hz, 2H), 7.18 (d, J=8.8 Hz, 2H), 7.97 (bs, 1H). 
MS (ESI): [M+1]+=222.1. 
(Z)-Methyl N'-cyano-N-(3-methoxyphenyl)carbamimidothioate (5j). Synthesized according to 
method A, compound 5j was obtained as a grey solid (yield 67%); mp 161-163 °C. 1H-NMR (d6-
DMSO) : 2.69 (s, 3H), 3.75 (s, 3H), 6.82 (ddd, J=7.4, 2.4 and 1.2 Hz, 1H), 7.00 (m, 2H), 7.03 (m, 
1H), 10.1 (bs, 1H). MS (ESI): [M+1]+=222.1. 
(Z)-Methyl N'-cyano-N-(3,4-dimethoxyphenyl)carbamimidothioate (5k). Synthesized according 
to method A, derivative 5k was obtained as a purple solid (yield 69%); mp 178-180 °C. 1H-NMR 
(CDCl3) : 2.42 (s, 3H), 3.89 (s, 3H), 3.90 (s, 3H), 6.86 (m, 3H), 7.95 (bs, 1H). MS (ESI): 
[M+1]+=252.3. 
(Z)-Methyl N'-cyano-N-(3,4,5-trimethoxyphenyl)carbamimidothioate (5l). Synthesized 
according to method A, compound 5l was obtained as a grey solid (yield 68%); mp 150-151 °C. 1H-
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NMR (CDCl3) : 2.45 (s, 3H), 3.81 (s, 3H), 3.86 (s, 6H), 6.54 (s, 2H), 7.96 (bs, 1H). MS (ESI): 
[M+1]+=282.3. 
(Z)-Methyl N'-cyano-N-(4-ethoxyphenyl)carbamimidothioate (5m). Synthesized according to 
method A, derivative 5m was obtained as a grey solid (yield 82%); mp 165-167 °C. 1H-NMR 
(CDCl3) : 1.43 (t, J=7.2 Hz, 3H), 2.41 (s, 3H), 4.02 (q, J=7.2 Hz, 2H), 6.88 (dd, J=7.0 and 2.2 Hz, 
2H), 7.17 (dd, J=7.0 and 2.2 Hz, 2H), 7.89 (bs, 1H). MS (ESI): [M+1]+=236.2. 
(Z)-Methyl N-benzo[d][1,3]dioxol-5-yl-N'-cyanocarbamimidothioate (5n). Synthesized 
according to method A, derivative 5n was obtained as a white solid (yield 73%); mp 191-193 °C. 
1H-NMR (CDCl3) : 2.42 (s, 3H), 6.04 (s, 2H), 6.79 (m, 3H), 7.81 (bs, 1H). MS (ESI): 
[M+1]+=236.2. 
General procedure B for the synthesis of compounds 6a-n. To a stirred suspension of derivative 
5a-n (2 mmol,) in dry THF (10 mL) was added hydrazine monohydrate (0.1 mL, 2 mmol, 1 equiv.), 
and the reaction mixture was heated under reflux for 6 h. After this time, the suspension was 
evaporated in vacuo to dryness, and the residue was suspended with ethyl ether (10 mL) and stirred 
for 10 min. The resultant solid was collected by filtration and then used for the next reaction 
without any purification. 
N3-Phenyl-1H-1,2,4-triazole-3,5-diamine (6a). Synthesized according to general procedure B, 
derivative 6a was obtained as a white solid (yield 74%); mp 160-161 °C. 1H-NMR (d6-DMSO) : 
5.83 (bs, 2H), 6.71 (t, J=7.8 Hz, 1H), 7.14 (t, J=7.8 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 8.57 (bs, 1H), 
11.1 (bs, 1H). MS (ESI): [M+1]+=176.1. 
N3-(4-Fluorophenyl)-1H-1,2,4-triazole-3,5-diamine (6b). Synthesized according to general 
procedure B, derivative 6b was obtained as a white solid (yield 83%); mp 216-218 °C. 1H-NMR 
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(d6-DMSO) : 5.84 (bs, 2H), 6.98 (t, J=8.8 Hz, 2H), 7.48 (m, 2H), 8.61 (bs, 1H), 11.1 (bs, 1H). MS 
(ESI): [M+1]+=194.2. 
N3-(p-Tolyl)-1H-1,2,4-triazole-3,5-diamine (6c). Synthesized according to general procedure B, 
compound 6c was obtained as a white solid (yield 92%); mp 185-187 °C. 1H-NMR (d6-DMSO) : 
2.19 (s, 3H), 5.81 (bs, 2H), 6.93 (d, J=8.6 Hz, 2H), 7.36 (dd, J=8.6 Hz, 2H), 8.42 (bs, 1H), 11.0 (bs, 
1H). MS (ESI): [M+1]+=190.2. 
N3-(m-Tolyl)-1H-1,2,4-triazole-3,5-diamine (6d). Synthesized according to general procedure B, 
compound 6d was obtained as a white solid (yield >95%); mp 112-114 °C. 1H-NMR (d6-DMSO) : 
2.21 (s, 3H), 5.81 (bs, 2H), 6.51 (d, J=7.2 Hz, 1H), 7.02 (t, J=7.2 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 
7.33 (s, 1H), 8.49 (bs, 1H), 11.1 (bs, 1H). MS (ESI): [M+1]+=220.2. 
N3-(3,4-Dimethylphenyl)-1H-1,2,4-triazole-3,5-diamine (6e). Synthesized according to general 
procedure B, derivative 6e was obtained as a white solid (yield >95%); mp 180-182 °C. 1H-NMR 
(d6-DMSO) : 2.10 (s, 3H), 2.13 (s, 3H), 5.77 (bs, 2H), 6.86 (d, J=8.2 Hz, 1H), 7.18 (d, J=8.2 Hz, 
1H), 7.26 (s, 1H), 8.35 (bs, 1H), 11.0 (bs, 1H). MS (ESI): [M+1]+=204.3. 
N3-(4-Ethylphenyl)-1H-1,2,4-triazole-3,5-diamine (6f). Synthesized according to general 
procedure B, compound 6f was obtained as a white solid (yield 92%); mp 187-189 °C. 1H-NMR 
(d6-DMSO) : 1.13 (t, J=7.6 Hz, 3H), 2.47 (q, J=7.6 Hz, 2H), 5.80 (bs, 2H), 6.96 (d, J=8.4 Hz, 2H), 
7.37 (d, J=8.4 Hz, 2H), 8.42 (bs, 1H), 11.0 (bs, 1H). MS (ESI): [M+1]+=204.3. 
N3-(4-Isopropylphenyl)-1H-1,2,4-triazole-3,5-diamine (6g). Synthesized according to general 
procedure B, compound 6g was obtained as a white solid (yield 60%); mp 156-158 °C. 1H-NMR 
(d6-DMSO) : 1.17 (d, J=6.8 Hz, 6H), 2.76 (m, 1H), 5.77 (bs, 2H), 6.99 (d, J=8.6 Hz, 2H), 7.37 (d, 
J=8.6 Hz, 2H), 8.44 (bs, 1H), 11.0 (bs, 1H). MS (ESI): [M+1]+=218.2. 
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N3-(4-n-Butylphenyl)-1H-1,2,4-triazole-3,5-diamine (6h). Synthesized according to general 
procedure B, derivative 6h was obtained as a white solid (yield 66%); mp 177-179 °C. 1H-NMR 
(d6-DMSO) : 0.88 (t, J=7.0 Hz, 3H), 1.26 (m, 2H), 1.48 (m, 2H), 2.41 (t, J=7.6 Hz, 2H), 5.80 (bs, 
2H), 6.94 (d, J=8.2 Hz, 2H), 7.36 (dd, J=8.2 Hz, 2H), 8.43 (bs, 1H), 11.1 (bs, 1H). MS (ESI): 
[M+1]+=232.3. 
N3-(4-Methoxyphenyl)-1H-1,2,4-triazole-3,5-diamine (6i). Synthesized according to general 
procedure B, derivative 6i was obtained as a grey solid (yield 88%); mp 200-201 °C. 1H-NMR (d6-
DMSO) : 3.67 (s, 3H), 5.76 (bs, 2H), 6.74 (dd, J=7.0 and 2.2 Hz, 2H), 7.39 (dd, J=7.0 and 2.2 Hz, 
2H), 8.32 (bs, 1H), 11.0 (bs, 1H). MS (ESI): [M+1]+=206.3. 
N3-(3-Methoxyphenyl)-1H-1,2,4-triazole-3,5-diamine (6j). Synthesized according to general 
procedure B, derivative 6j was obtained as a red solid (yield >95%); mp 117-119 °C. 1H-NMR (d6-
DMSO) : 3.76 (s, 3H), 5.78 (bs, 2H), 6.88 (dd, J=7.4 and 2.4 Hz, 1H), 7.02 (m, 2H), 7.05 (m, 1H), 
8.47 (bs, 1H), 11.1 (bs, 1H). MS (ESI): [M+1]+= 206.2. 
N3-(3,4-Dimethoxyphenyl)-1H-1,2,4-triazole-3,5-diamine (6k). Synthesized according to general 
procedure B, derivative 6k was obtained as a purple solid (yield 72%); mp 158-160 °C. 1H-NMR 
(d6-DMSO) : 3.66 (s, 3H), 3.75 (s, 3H), 5.75 (bs, 2H), 6.74 (d, J=8.8 Hz, 1H), 6.98 (m, 1H), 7.23 
(d, J=2.4 Hz, 1H), 8.32 (bs, 1H), 11.2 (bs, 1H). MS (ESI): [M+1]+=236.2. 
N3-(3,4,5-Trimethoxyphenyl)-1H-1,2,4-triazole-3,5-diamine (6l). Synthesized according to 
general procedure B, derivative 6l was obtained as a white solid (yield 68%); mp 241-243 °C. 1H-
NMR (d6-DMSO) : 3.56 (s, 3H), 3.70 (s, 6H), 5.84 (bs, 2H), 6.90 (s, 2H), 8.43 (bs, 1H), 11.1 (bs, 
1H). MS (ESI): [M+1]+=266.3. 
N3-(4-Ethoxyphenyl)-1H-1,2,4-triazole-3,5-diamine (6m). Synthesized according to general 
procedure B, derivative 6m was obtained as a purple solid (yield 94%); mp 200-201 °C. 1H-NMR 
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(d6-DMSO) : 1.28 (t, J=7.0 Hz, 3H), 3.93 (q, J=7.0 Hz, 2H), 5.76 (bs, 2H), 6.72 (dd, J=7.0 and 2.0 
Hz, 2H), 7.38 (dd, J=7.0 and 2.0 Hz, 2H), 8.31 (bs, 1H), 11.0 (bs, 1H). MS (ESI): [M+1]+=220.2. 
N3-(Benzo[d][1,3]dioxol-5-yl)-1H-1,2,4-triazole-3,5-diamine (6n). Synthesized according to 
general procedure B, compound 6n was obtained as a brown solid (yield 73%); mp 206-208 °C. 1H-
NMR (d6-DMSO) : 5.80 (bs, 2H), 5.88 (s, 2H), 6.69 (d, J=8.2 Hz, 1H), 6.87 (dd, J=8.2 and 2.2 Hz, 
1H), 7.26 (d, J=2.2 Hz, 1H), 8.45 (bs, 1H), 11.1 (bs, 1H). MS (ESI): [M+1]+=220.2. 
General procedure C for the synthesis of compounds 3a-n and 7a-n. To a stirred solution of the 
appropriate 1,2,4-triazole 6a-n (1 mmol) in dry pyridine (10 mL) cooled at -5 °C was added 
3’,4’,5’-trimethoxybenzoylchloride (230 mg, 1.1 mol, 1.1 equv.) in small portions. The reaction 
mixture was kept for 30 min at -5 °C and then overnight at room temperature. Pyridine was then 
removed by evaporation under reduced pressure. To the residue was added CH2Cl2, and the organic 
phase was washed with saturated aq. NaHCO3, water and brine and dried over Na2SO4. The reaction 
mixture was filtered, and the solvent was removed in vacuo. The crude residue was purified by 
column chromatography on silica gel using a mixture of CH2Cl2-methanol (9.5:0.5) as eluent to 
separate the two regioisomeric 3’,4’,5’-trimethoxybenzoyl triazoles 3a-n and 7a-n, with the former 
compounds 3a-n characterized by the lower Rf.  
(3-(Phenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone (3a). 
Synthesized according to method C, derivative 3a was obtained as a yellow solid (yield 56%); mp 
181-183 °C. 1H-NMR (d6-DMSO) : 3.79 (s, 3H), 3.86 (s, 6H), 6.86 (t, J=7.2 Hz, 1H), 7.22 (t, 
J=8.4 Hz, 2H), 7.56 (d, J=7.6 Hz, 2H), 7.68 (s, 2H), 7.93 (bs, 2H), 9.35 (s, 1H). 13C-NMR (d6-
DMSO) : 55.96 (2C), 60.23, 108.66 (2C), 116.57 (2C), 120.37, 127.17, 128.57 (2C), 140.89, 
141.37, 152.07 (2C), 157.58, 158.19, 165.37. MS (ESI): [M]+=369.8. Anal. (C18H19N5O4) C, H, N.  
(3-(4-Fluorophenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone 
(3b). Synthesized according to method C, compound 3b was obtained as a yellow solid (yield 60%); 
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mp 218-220 °C. 1H-NMR (d6-DMSO) : 3.79 (s, 3H), 3.86 (s, 6H), 7.07 (t, J=8.8 Hz, 2H), 7.56 (dd, 
J=8.8 and 3.4 Hz, 2H), 7.61 (s, 2H), 7.83 (bs, 2H), 9.38 (s, 1H). 13C-NMR (d6-DMSO) : 55.98 
(2C), 60.22, 108.58 (2C), 114.99, 115.21, 117.81, 117.88, 127.15, 137.40, 141.35, 152.08 (2C), 
155.17, 157.60, 158.19, 165.41. MS (ESI): [M]+=387.7. Anal. (C18H18FN5O4) C, H, N.  
(3-(4-Tolylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone (3c). 
Synthesized according to method C, compound 3c was obtained as a yellow solid (yield 55%); mp 
235-237 °C. 1H-NMR (d6-DMSO) : 2.22 (s, 3H), 3.79 (s, 3H), 3.88 (s, 6H), 6.97 (d, J=8.6 Hz, 
2H), 7.44 (d, J=8.6 Hz, 2H), 7.68 (s, 2H), 7.81 (bs, 2H), 9.22 (s, 1H). 13C-NMR (d6-DMSO) : 
20.26, 95.96 (2C), 60.22, 108.63 (2C), 116.68 (2C), 120.36, 127.20, 128.87 (2C), 138.41, 141.32, 
152.15 (2C), 157.56, 158.26, 165.33. MS (ESI): [M]+=383.5. Anal. (C19H21N5O4) C, H, N.  
(3-(3-Tolylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone (3d). 
Synthesized according to method C, derivative 3d was obtained as a yellow solid (yield 61%); mp 
165-167 °C. 1H-NMR (d6-DMSO) : 2.30 (s, 3H), 3.78 (s, 3H), 3.85 (s, 6H), 6.65 (d, J=7.4 Hz, 
1H), 7.08 (t, J=7.8 Hz, 1H), 7.34 (s, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.61 (s, 2H), 7.80 (bs, 2H), 9.26 
(s, 1H). 13C-NMR (d6-DMSO) : 21.26, 55.99 (2C), 60.22, 108.52 (2C), 113.77, 117.16, 120.98, 
127.40, 128.38, 137.70, 140.87, 141.20, 152.05 (2C), 157.40, 158.14, 165.63. MS (ESI): 
[M]+=383.5. Anal. (C19H21N5O4) C, H, N. 
(3-(3,4-Dimethylphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3e). Synthesized according to method C, compound 3e was obtained as a yellow solid 
(yield 48%); mp 169-171 °C. 1H-NMR (d6-DMSO) : 2.12 (s, 6H), 3.80 (s, 3H), 3.85 (s, 6H), 6.93 
(d, J=8.0 Hz, 1H), 7.31 (s, 1H), 7.35 (d, J=8.0 Hz, 1H), 7.61 (s, 2H), 7.78 (bs, 2H), 9.14 (s, 1H). 
13C-NMR (d6-DMSO) : 18.61, 19.75, 55.98 (2C), 60.22, 108.51 (2C), 114.01, 117.93, 127.45, 
127.69, 129.42, 136.11, 138.74, 141.17, 152.03 (2C), 157.38, 158.21, 165.57. MS (ESI): 
[M]+=397.7. Anal. (C20H23N5O4) C, H, N.  
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(3-(4-Ethylphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone 
(3f). Synthesized according to method C, compound 3f was obtained as a yellow solid (yield 54%); 
mp 194-196 °C. 1H-NMR (d6-DMSO) : 1.14 (t, J=8.4 Hz, 3H), 3.51 (d, J=8.4 Hz, 2H), 3.78 (s, 
3H), 3.97 (s, 6H). 7.02 (d, J=8.6 Hz, 2H), 7.46 (d, J=8.6 Hz, 2H), 7.68 (s, 2H), 7.81 (bs, 2H), 8.22 
(s, 1H). 13C-NMR (d6-DMSO) : 16.35, 31.15, 56.41 (2C), 61.68, 109.07 (2C), 127.14 (2C), 
127.66, 128.22 (2C), 135.97, 139.08, 141.76, 152.50 (2C), 156.03, 158.74, 165.78. MS (ESI): 
[M]+=397.5. Anal. (C21H26N5O4) C, H, N. 
(3-(4-Isopropylphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3g). Synthesized according to method C, derivative 3g was obtained as a yellow solid 
(yield 52%); mp 197-199 °C. 1H-NMR (d6-DMSO) : 1.14 (d, J=6.8 Hz, 6H), 2.80 (m, 1H), 3.77 (s, 
3H), 3.87 (s, 6H), 7.06 (d, J=8.2 Hz, 2H), 7.46 (d, J=8.2 Hz, 2H), 7.68 (s, 2H), 7.81 (bs, 2H), 9.21 
(s, 1H). 13C-NMR (d6-DMSO) : 24.06 (2C), 32.65, 55.95 (2C), 60.23, 108.65 (2C), 116.75 (2C), 
120.39 (2C), 124.28, 126.24, 138.70, 140.25, 152.05 (2C), 157.58, 158.32, 165.32. MS (ESI): 
[M]+=411.7. Anal. (C21H25N5O4) C, H, N. 
(3-(4-Butylphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone 
(3h). Synthesized according to method C, compound 3h was obtained as a yellow solid (yield 54%); 
mp 134-136 °C. 1H-NMR (d6-DMSO) : 0.88 (t, J=7.2 Hz, 3H), 1.29 (m, 2H), 1.50 (m, 2H), 2.44 (t, 
J=7.6 Hz, 2H), 3.80 (s, 3H), 3.87 (s, 6H), 7.00 (d, J=8.6 Hz, 2H), 7.45 (d, J=8.6 Hz, 2H), 7.68 (s, 
2H), 7.81 (bs, 2H), 9.22 (s, 1H). 13C-NMR (d6-DMSO) : 13.78, 21.66, 33.36, 34.09, 55.94 (2C), 
60.23, 108.64 (2C), 116.67 (2C), 120.38, 127.21, 128.30 (2C), 134.05, 138.61, 152.05 (2C), 157.57, 
158.29, 165.33. MS (ESI): [M]+=425.8. Anal. (C22H27N5O4) C, H, N. 
(3-(4-Methoxyphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3i). Synthesized according to method C, compound 3i was obtained as a yellow solid 
(yield 64%); mp 196-197 °C. 1H-NMR (d6-DMSO) : 3.67 (s, 3H), 3.77 (s, 3H), 3.84 (s, 6H), 6.77 
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(d, J=8.8 Hz, 2H), 7.46 (d, J=8.8 Hz, 2H), 7.66 (s, 2H), 7.79 (bs, 2H), 9.11 (s, 1H). 13C-NMR (d6-
DMSO) : 55.07, 55.85 (2C), 60.13, 108.53 (2C), 113.76 (2C), 127.81 (2C), 127.11, 134.24, 
141.21, 151.95 (2C), 153.19, 157.48, 158.29, 165.16. MS (ESI): [M]+=399.8. Anal. (C19H21N5O5) 
C, H, N.  
(3-(3-Methoxyphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3j). Synthesized according to method C, compound 3j was obtained as a yellow solid 
(yield 42%); mp 178-180 °C. 1H-NMR (d6-DMSO) : 3.65 (s, 3H), 3.78 (s, 3H), 3.86 (s, 6H), 6.44 
(m, 1H), 7.12 (m, 2H), 7.26 (s, 1H), 7.61 (s, 2H), 7.81 (bs, 2H), 9.32 (s, 1H). 13C-NMR (d6-DMSO) 
: 54.76, 55.94 (2C), 60.19, 102.99, 105.19, 108.45 (2C), 109.37, 127.36, 129.29, 141.22, 142.01, 
152.07 (2C), 157.45, 158.12, 159.78, 165.63. MS (ESI): [M]+=399.6. Anal. (C19H21N5O5) C, H, N. 
(3-(3,4-Dimethoxyphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3k). Synthesized according to method C, derivative 3k was obtained as a yellow solid 
(yield 51%); mp 170-171 °C. 1H-NMR (d6-DMSO) : 3.67 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 3.83 
(s, 6H), 6.77 (d, J=8.6 Hz, 1H), 7.08 (dd, J=8.6 and 2.2 Hz, 1H), 7.22 (d, J=2.2 Hz, 1H), 7.56 (s, 
2H), 7.78 (bs, 2H), 9.09 (s, 1H). 13C-NMR (d6-DMSO) : 55.16 (2C), 56.00 (2C), 60.20, 102.58, 
108.25, 108.33 (2C), 112.61, 127.61, 134.95, 141.06, 142.85, 148.90, 152.02 (2C), 157.35, 158.28, 
165.71. MS (ESI): [M]+=429.8. Anal. (C20H23N5O6) C, H, N.  
(3-(3,4,5-Trimethoxyphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3l). Synthesized according to method C, derivative 3l was obtained as a yellow solid 
(yield 48%); mp 172-174 °C. 1H-NMR (d6-DMSO) : 3.56 (s, 3H), 3.58 (s, 3H), 3.75 (s, 6H), 3.79 
(s, 6H), 6.91 (s, 2H), 7.41 (s, 2H), 7.75 (bs, 2H), 9.16 (s, 1H). 13C-NMR (d6-DMSO) : 55.44 (2C), 
56.08 (2C), 60.17 (2C), 94.92 (2C), 108.04 (2C), 128.01, 131.38, 137.16, 140.87, 151.98 (2C), 
152.84 (2C), 157.09, 158.09, 166.29. MS (ESI): [M]+=459.8. Anal. (C21H25N5O7) C, H, N. 
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(3-(4-Ethoxyphenylamino)-5-amino-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) methanone 
(3m). Synthesized according to method C, compound 3c was obtained as a yellow solid (yield 
54%); mp 176-178 °C. 1H-NMR (d6-DMSO) : 1.29 (t, J=6.8 Hz, 3H), 3.79 (s, 3H), 3.86 (s, 6H), 
3.93 (q, J=6.8 Hz, 2H), 6.77 (d, J=9.0 H, 2H), 7.46  (d, J=9.0 H, 2H), 7.68 (s, 2H), 7.80 (bs, 2H), 
9.11 (s, 1H). 13C-NMR (d6-DMSO) : 14.73, 55.95 (2C), 60.22, 63.09, 108.62 (2C), 114.44 (2C), 
127.86 (2C), 127.22, 134.27, 141.29, 152.05 (2C), 152.51, 157.57, 158.38, 165.25. MS (ESI): 
[M]+=413.8. Anal. (C20H23N5O5) C, H, N.  
(5-Amino-3-(benzo[d][1,3]dioxol-5-ylamino)-1H-1,2,4-triazol-1-yl)(3,4,5-trimethoxyphenyl) 
methanone (3n). Synthesized according to method C, compound 3n was obtained as a yellow solid 
(yield 46%); mp 200-201 °C. 1H-NMR (d6-DMSO) : 3.78 (s, 3H), 3.86 (s, 6H), 5.93 (s, 2H), 6.76 
(d, J=8.4 Hz, 1H), 6.92 (dd, J=8.4 and 2.2 Hz, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.65 (s, 2H), 7.81 (bs, 
2H), 9.23 (s, 1H). 13C-NMR (d6-DMSO) : 55.97 (2C), 60.22, 99.01, 100.67, 108.12, 108.51 (2C), 
108.93, 127.25, 135.73, 140.71, 141.28, 147.23, 152.06 (2C), 157.53, 158.26, 165.34. MS (ESI): 
[M]+=413.8. Anal. (C19H19N5O6) C, H, N.  
X-ray structure determination. X-ray diffraction data for compound 3c were collected at room 
temperature, 295 K, on a Nonius Kappa CCD diffractometer with graphite monochromated Mo K 
radiation ( = 0.7107 Å). The structure was solved by direct methods (SIR97)35 and refined 
(SHELXL-97)36 by full matrix least squares with anisotropic non-hydrogen atoms. The hydrogen 
atoms were included on calculated positions, riding on their carrier atoms, except for those bound to 
nitrogen. The latter were refined isotropically. 
Crystal data: C19H21N5O4; orthorhombic, space group Pbca, a =  7.6945(1), b = 18.7364(4), c = 
26.0711(5) Å, V = 3758.6(1) Å3, Z = 8, Dc =  1.355 g cm-3. Intensity data collected with    26°; 
3677 independent reflections measured; 2412 observed [I 2(I)]. Final R index = 0.0471 (observed 
reflections), Rw = 0.1395 (all reflections), S = 1.022. Complete crystallographic data have been 
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deposited with the Cambridge Crystallographic Data Centre as supplementary publication number 
CCDC N. 984800. Copies of that data can be obtained, free of charge, via 
www.ccdc.cam.ac.uk./conts/retrieving.html or on application to CCDC, 12 Union Road, Cambridge 
CB2 1EZ, U.K. [fax: +44(0)-1223-336033, e-mail: deposit@ccdc.cam.ac.uk]. 
Cell growth conditions and antiproliferative assay. Human T-leukemia (CCRF-CEM and Jurkat) 
and human B-leukemia (SEM) cells were grown in RPMI-1640 medium (Gibco, Milano, Italy). 
Breast adenocarcinoma (MCF-7), human cervix carcinoma (HeLa), and human colon 
adenocarcinoma (HT-29) cells were grown in DMEM medium (Gibco, Milano, Italy), all 
supplemented with 115 units/mL penicillin G (Gibco, Milano, Italy), 115 μg/mL streptomycin 
(Invitrogen, Milano, Italy), and 10% fetal bovine serum (Invitrogen, Milano, Italy). CEMVbl-100 cells 
are a multidrug-resistant line selected against vinblastine.20 LoVoDoxo cells are a doxorubicin 
resistant subclone of LoVo cells21 and were grown in complete Ham’s F1β medium supplemented 
with doxorubicin (0.1 µg/mL). LoVoDoxo and CEMVbl-100 were a kind gift of Dr. G. Arancia (Istituto 
Superiore di Sanità, Rome, Italy). Stock solutions (10 mM) of the different compounds were 
obtained by dissolving them in DMSO. Individual wells of a 96-well tissue culture microtiter plate 
were inoculated with 100 μL of complete medium containing 8 × 103 cells. The plates were 
incubated at 37 °C in a humidified 5% CO2 incubator for 18 h prior to the experiments. After 
medium removal, 100 μL of fresh medium containing the test compound at different concentrations 
was added to each well in triplicate and incubated at 37 °C for 72 h. The percentage of DMSO in 
the medium never exceeded 0.25%. This was also the maximum DMSO concentration in all cell-
based assays described below. Cell viability was assayed by the (3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide test as previously described.37 The IC50 was defined as the compound 
concentration required to inhibit cell proliferation by 50%, in comparison with cells treated with the 
maximum amount of DMSO (0.25%) and considered as 100% viability.  
Peripheral blood lymphocytes (PBL) from healthy donors were obtained by separation on 
Lymphoprep (Fresenius KABI Norge AS) gradient. After extensive washing, cells were 
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resuspended (1.0 x 106 cells/mL) in RPMI-1640 with 10% fetal bovine serum and incubated 
overnight. For cytotoxicity evaluations in proliferating PBL cultures, non-adherent cells were 
resuspended at 5 x 105 cells/mL in growth medium, containing 2.5 µg/mL PHA (Irvine Scientific). 
Different concentrations of the test compounds were added, and viability was determined 72 h later 
by the MTT test. For cytotoxicity evaluations in resting PBL cultures, non-adherent cells were 
resuspended (5 x 105 cells/mL) and treated for 72 h with the test compounds, as described above.  
Effects on tubulin polymerization and on colchicine binding to tubulin. To evaluate the effect 
of the compounds on tubulin assembly in vitro,38a varying concentrations of compounds were 
preincubated with 10 M bovine brain tubulin in 0.8 M monosodium glutamate (pH adjusted to 6.6 
with HCl in a 2.0 M stock solution) at γ0 ˚C and then cooled to 0 ˚C. After addition of 0.4 mM 
GTP, the mixtures were transferred to 0 C cuvettes in a recording spectrophotometer and warmed 
to 30 °C. Tubulin assembly was followed turbidimetrically at 350 nm. The IC50 was defined as the 
compound concentration that inhibited the extent of assembly by 50% after a 20 min incubation. 
The capacity of the test compounds to inhibit colchicine binding to tubulin was measured as 
described,38b except that the reaction mixtures contained 1 M tubulin, 5 M [3H]colchicine and 5 
M test compound. 
Molecular modeling. All molecular modeling studies were performed on a MacPro dual 2.66GHz 
Xeon running Ubuntu 12.04. The tubulin structure was downloaded from the PDB data bank 
(http://www.rcsb.org/ - PDB code: 1SA0).39 Hydrogen atoms were added to the protein, using the 
Protonate 3D routine of the Molecular Operating Environment (MOE).40 Ligand structures were 
built with MOE and minimized using the MMFF94x forcefield until a RMSD gradient of 0.05 kcal 
mol-1 Å-1 was reached. The docking simulations were performed using PLANTS.41 
Flow cytometric analysis of cell cycle distribution. 5 × 105 HeLa or Jurkat cells were treated with 
different concentrations of the test compounds for 24 h. After the incubation period, the cells were 
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collected, centrifuged, and fixed with ice-cold ethanol (70%). The cells were then treated with lysis 
buffer containing RNase A and 0.1% Triton X-100 and then stained with PI. Samples were analyzed 
on a Cytomic FC500 flow cytometer (Beckman Coulter). DNA histograms were analyzed using 
MultiCycle for Windows (Phoenix Flow Systems). 
Apoptosis assay. Cell death was determined by flow cytometry of cells double stained with annexin 
V/FITC and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure the surface 
exposure of PS on apoptotic cells according to the manufacturer’s instructions (Annexin-V Fluos, 
Roche Diagnostics). 
Western blot analysis. HeLa cells were incubated in the presence of 3c and after different times 
were collected, centrifuged, and washed two times with ice cold phosphate buffered saline (PBS). 
The pellet was then resuspended in lysis buffer. After the cells were lysed on ice for 30 min, lysates 
were centrifuged at 15000 x g at 4 °C for 10 min. The protein concentration in the supernatant was 
determined using the BCA protein assay reagents (Pierce, Italy). Equal amounts of protein (10 μg) 
were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(7.5−15% acrylamide gels) and transferred to PVDF Hybond-P membrane (GE Healthcare). 
Membranes were blocked with a bovine serum albumin (BSA) solution (BSA 5% in Tween PBS 
1X), the membranes being gently rotated overnight at 4 °C. Membranes were then incubated with 
primary antibodies against Bcl-2, Bax, PARP, cleaved caspase-9, cdc25c (Cell Signaling), caspase-
3 (Alexis), H2AX (Cell Signaling), p53 (Cell Signaling), cyclin B (Cell Signaling), p-cdc2Tyr15 (Cell 
Signaling), pβ1 (Cell Signaling), or ȕ-actin (Sigma-Aldrich) for 2 h at room temperature. 
Membranes were next incubated with peroxidase labeled secondary antibodies for 60 min. All 
membranes were visualized using ECL Select (GE Healthcare) and exposed to Hyperfilm MP (GE 
Healthcare). To ensure equal protein loading, each membrane was stripped and reprobed with anti-
ȕ-actin antibody. 
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Antivascular activity. HUVECs were prepared from human umbilical cord veins, as previously 
described.33 The adherent cells were maintained in M200 medium supplemented with LSGS (Low 
Serum Growth Supplement), containing FBS, hydrocortisone, hEGF, bFGF, heparin, 
gentamycin/amphotericin (Life Technologies, Monza, Italy). Once confluent, the cells were 
detached by trypsin–EDTA solution and used in experiments from the first to sixth passages. 
The motility assay for HUVECs was based on “scratch” wounding of a confluent monolayer.42 
Briefly, HUVECs (1x105) were seeded onto 0.1% collagen type I (BD Biosciences, Italy)-coated six 
well plates in complete medium until a confluent monolayer was formed. The cells were wounded 
using a pipette tip, and wells were washed with PBS to remove the detached cells. Then, the cells 
were treated with the test compounds, and at different times from the scratch, the cells were 
photographed under a light microscope. At all indicated time points, the wound width was measured 
in four areas and compared with the initial width. 
Matrigel matrix (Basement Membrane Matrix, BD Biosciences, Italy) was kept at 4 °C for 3 h, 
when 230 µL of Matrigel solution was added to each well of a 24-well plate. After gelling at 37°C 
for 30 min, gels were overlaid with 500 µL of medium containing 6 x 104 HUVECs. The cells were 
incubated over Matrigel for 6 h to allow capillary tubes to form. Different concentrations of test 
compound were added in the cultures and incubated for different times, and the disappearance of 
existing vasculature was monitored and photographed (five fields for each well: the four quadrants 
and the center) at a 10x magnification. Phase contrast images were recorded using a digital camera 
and saved as TIFF files. Image analysis was carried out using the ImageJ image analysis software, 
and the following dimensional parameters (percent area covered by HUVECs and total length of 
HUVECs network per field) and topological parameters (number of meshes and branching points 
per fields) were estimated.32 Values were expressed as percent change from control cultures grown 
with complete medium. 
Antitumor activity in vivo. The in vivo cytotoxic activity of compound 3c was investigated using a 
syngeneic murine hepatocellular carcinoma cell line (BNL 1ME A.7R.1) in Balb/c mice.34 Male 
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mice, 8 weeks old, were purchased from Harlan (S. Pietro al Natisone Udine, Italy), and tumors 
were induced by a subcutaneous injection in their dorsal region of 107 cells in 200 µL of sterile 
PBS. Animals were randomly divided into four groups, and, starting on the second day, the first 
group was daily dosed intraperitoneally (i.p.) with 7 µL/kg of free vehicle (0.9% NaCl containing 
5% polyethylene glycol 400 and 0.5% Tween 80). Groups two and three were treated with 
compound 3c at the doses of 5 and 10 mg/kg body weight, respectively. The fourth group received 
the reference compound CA-4P at the dose of 5 mg/kg body weight. Both compound 3c and CA-4P 
were dissolved in free vehicle. Tumor sizes were measured daily for 7 days using a pair of calipers. 
In particular, the tumor volume (V) was calculated by the rotational ellipsoid formula: V = A x B2/2, 
where A is the longer diameter (axial) and B is the shorter diameter (rotational). All experimental 
procedures followed guidelines recommended by the Institutional Animal Care and Use Committee 
of Padova University. 
Statistical Analysis. Unless indicated otherwise, the results are presented as the mean ± SEM. The 
differences between different treatments were analyzed using the two-sided Student’s t test. P 
values lower than 0.05 were considered significant. 
Supporting information available. Detailed characterization of synthesized compounds 7a-c, 7g-h 
and 7k-l. Immunofluorescence analysis of tubulin network and apoptosis assay on HeLa cells. This 
material is available free of charge via the Internet at http://pubs.acs.org. 
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Abbreviations. CA-4, combretastatin A-4; VDA, vascular disrupting agent; PI, propidium iodide; 
PS, phosphatidylserine; PARP, polyADP-ribose polymerase; PBL, peripheral blood lymphocytes; 
PHA, phytohemaglutinin; FITC, fluorescein isothiocyanate; BSA, bovine serum albumin; HE, 
hydroxyethidine; PBS, phosphate-buffered saline; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; HUVEC, human umbilical vein endothelial cell; LSGS, low 
serum growth supplement. 
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Table 1. In vitro cell growth inhibitory effects of compounds 3a-n and CA-4 (1) 
 
 
Compd  
IC50 a(nM) 
Jurkat CCRF-CEM SEM HeLa HT-29 A549 MCF-7 
3a 1200±270 1000±90 1200±190 >10,000 6200±1200 >10,000 500±240 
3b 1900±400 2200±400 2400±210 410±70 2000±700 3800±160 370±30 
3c 0.81±0.03 0.21±0.04 0.51±0.10 3.2±1.3 0.82±0.10 0.51±0.22 1.0±0.61 
3d 42±16 330±60 30±10 440±50 460±80 870±30 15±3.2 
3e 2.0±0.11 0.81±0.10 0.40±0.11 2.0±0.82 3.0±0.91 1.0±0.82 4.0±0.21 
3f 1.0±0.09 3.0±0.09 0.81±0.21 6.0±1.0 0.21±0.08 0.92±0.51 5.0±1.0 
3g 520±40 1800±90 500±10 130±28 800±100 550±70 510±70 
3h >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 5200±110 
3i 51±10 1000±200 44±16 120±30 480±15 2400±100 260±80 
3j 7.2±2.0 120±30 1.0±0.4 30±1.2 700±32 54±4.3 11±4.2 
3k >10,000 9000±330 >10,000 >10,000 >10,000 >10,000 >10,000 
3l >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
3m 2500±220 2000±100 1900±170 2100±800 3700±400 6200±540 34±18 
3n 24±7.2 40±3.3 30±6 930±54 60±10 150±50 19±5.2 
CA-4 5±0.6 12±2.5 5±0.1 4±0.1 3100±100 180±50 370±100 
aIC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± 
SE from the dose-response curves of at least three independent experiments carried out in triplicate. 
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Table 2. Cytotoxicity of 3c and 3f in human non-cancer cells 
 
 
 
 
 
 
 
a
 
Compound concentration required to reduce cell growth inhibition by 50%. 
b
 PBL not stimulated with PHA. 
c PBL stimulated with PHA. 
Values are the mean ± SEM for three separate experiments. n.d. not determined 
 
 
Cell line  
IC50 (µM)
 a 
3c 3f 
PBLresting
b 31.2±8.7 34.0±11.7 
PBLPHA
c 8.5±2.6 8.8±2.7 
HUVEC 11.9±3.8 n.d. 
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Table 3. In vitro cell growth inhibitory effects of compounds 3c on drug resistant cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
aIC50=compound concentration required to inhibit tumor cell proliferation by 50%. Data are 
presented as the mean ± SE from the dose-response curves of two independent experiments 
performed in triplicate. 
bThe values express the ratio between IC50 determined in resistant and non-resistant cell 
lines. 
 
 
 
 
 
Compd 
IC50 a(nM)  
LoVo LoVoDoxo Resistance ratiob 
3c 0.9±0.1 1.1± 0.5 1.2 
Doxorubicin 95.6 ± 43.2 11296 ± 356 118 
 CEM CEM Vbl100 Resistance ratiob 
3c 0.21 ± 0.4 1.2± 0.5 5.7 
Vinblastine 1.0 ± 0.3 193 ± 39 193 
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Table 4. Inhibition of tubulin polymerization and colchicine binding by compounds 1a, 3c-g, 3i-j 
and 3n. 
 
Compound 
Tubulin assembly
a 
IC50±SD (M) Colchicine binding 
b 
% ±SD 
3c 0.75±0.1 92±2 
3d 1.8±0.0 67±1 
3e 1.2±0.0 83±1 
3f 1.4±0.0 80±2 
3g 13±0.7 n.d 
3i 3.70.4 48±2 
3j 2.50.0 70±0.9 
3n 2.00.0 51±0.3 
1a 1.2±0.1 98±0.5 
a Inhibition of tubulin polymerization. Tubulin was at 10 M. 
b Inhibition of [3H]colchicine binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 M, respectively. 
n.d: not determined 
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Figure Legends 
Figure 1. ORTEP view of compound 3c displaying the thermal ellipsoids at 30% probability. 
Figure 2. Panel A. Proposed binding for 3c (in grey) in the colchicine site. Co-Crystallized DAMA-
colchicine is shown in green. Panel B. Representation of the binding mode of 3c in the colchicine 
site, with a summary of the SARs observed for the reported series of compounds. Panel C. 
Superposition of the conformation obtained from the docking simulations (in grey) and the crystal 
structure (in yellow) of 3c. 
Figure 3. Percentage of cells in each phase of the cell cycle in HeLa (Panel A) and Jurkat cells 
(Panel B) treated with 3c at the indicated concentrations for 24 h. Cells were fixed and labeled with 
PI and analyzed by flow cytometry as described in the experimental section. Data are represented as 
mean ± SEM of three independent experiments. 
Figure 4. Effects of 3c on G2/M regulatory proteins (Panel A) and on p53, p21 and H2AX 
expression (panel B). HeLa cells were treated for 24 or 48 h with the indicated concentration of 3c. 
The cells were harvested and lysed for the detection of cyclin B1, p-cdc2Tyr15 and cdc25C (panel A) 
or p53, p21 and H2AX expression (panel B) by western blot analysis. To confirm equal protein 
loading, each membrane was stripped and reprobed with anti--actin antibody. 
Figure 5. Flow cytometric analysis of apoptotic cells after treatment of HeLa cells (Panel A) or 
Jurkat cells (Panel B) with 3c at the indicated concentrations after incubation for 24 or 48 h. The 
cells were harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data 
are represented as mean ± SEM of three independent experiments. 
Figure 6. (A). Western blot analysis of caspase-3, cleaved caspase-9, PARP Bcl-2 and Bax after 
treatment of HeLa cells with 3c at the indicated concentrations and for the indicated times., To 
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confirm equal protein loading, each membrane was stripped and reprobed with anti--actin 
antibody. 
Figure 7. Compound 3c has antivascular activity in vitro. Panel A. Confluent HUVECs in a 
monolayer were wounded, and cells treated with different concentrations of 3c and at different times 
were photographed, 7x magnification; bar=100 µm. The dotted lines define the areas lacking cells. 
Panel B. The graph shows the quantitative effect of 3c. Migration was quantified by measuring the 
gap closure at the indicated times as shown in panel A. Data are represented as mean ± S.E.M. of 
three independent experiments. *p<0.05, **p<0.01 vs control. Panel C. Inhibition of endothelial cell 
capillary-like tubule formation by 3c. Tubule formation on Matrigel was carried out as described in 
the Experimental section. Representative pictures (10x magnification; bar=100 µm) of preformed 
capillary-like tubules treated with increasing concentrations of 3c for 1 or 3 h. Panel D. Quantitative 
analysis of the effects of 3c on the dimensional and topological parameters of the preformed 
capillary-like tubule networks, after a 3 h treatment. Data were represented as mean ± S.E.M. of 
three independent experiments. *p<0.05, **p<0.01 vs. control. 
Figure 8. Inhibition of mouse allograft tumor growth in vivo by compound 3c. (A). Male mice were 
injected subcutaneously in their dorsal region with 107 BNL 1MEA.7R.1 cells, a syngeneic 
hepatocellular carcinoma cell line. Tumor-bearing mice were administered the vehicle, as control, 
or the indicated doses of 3c or CA-4P as reference compound at the concentration of 5 mg/kg. Daily 
injections were given intraperitoneally starting on day 1. The figure shows the average measured 
tumor volumes (A) and body weights of the mice (B) recorded at the beginning and at the end of the 
treatments. Data are presented as mean ± SEM of tumor volume and body weight at each time point 
for 5 animals per group. *p<0.05, **p<0.01 vs. control.  
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Chart 1. Inhibitors of Tubulin Polymerization 
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Scheme 1 
 
Reagents. a: ArNH2, i-PrOH, reflux; b: NH2NH2.H2O, THF, reflux; c: 3',4',5'-(OMe)3C6H2COCl, 
pyridine, 0 °C.
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